151 research outputs found
Clinical Efficacy and Safety of Acupuncture Rehabilitation for Post-stroke Depression: A Systematic Review and Meta-analysis
Objective: The most important and common psychiatric disorders after stroke include post-stroke depression, which can lead to a variety of negative health outcomes. This study was calculated to estimate the security and effectiveness of acupuncture rehabilitation in curative effects for post-stroke depression patients. Methods: As of July 2022, PubMed, Embase, Web of Science, Cochrane Library, and China National Knowledge Infrastructure were searched through electronic databases. Eligibility criteria RCTs evaluate RCTs of acupuncture rehabilitation on treatment events in depressed patients after stroke, compared to a control group. Results: Eight studies were included (n = 16,422). When combined with antidepressant/sham acupuncture efficacy, acupuncture intervention observably reduced HAMD scores (MD= -0.55,95% CI= -1.57 to -0.48, P=0.30, I²= 0%). Meanwhile, acupuncture rehabilitation also reduced BI scores (MD= 1.87,95%CI= -3.77-7.51, P=0.51, I²= 0%) and CGI-S score (MD=0.43,95% CI = 0.06-0.77, P =0.01, I² = 0%) compared with antidepressants / sham acupuncture. Second, the occurrence rate of combined negative events was dramatically lesser in the acupuncture groups, as indicated by the SERS scores (MD= -4.85,95% CI= 5.67 to -4.04, P <0.00001, I² = 0%) of the acupuncture groups and the antidepressant/sham acupuncture groups. Furthermore, the overall clinical outcome was observably better in the acupuncture groups (MD=1.58,95% CI =0.813.09, P =0.18, I² = 0%). Conclusion: Acupuncture rehabilitation intervention for post-stroke depression is safer and more effective than antidepressant/sham acupuncture
Recommended from our members
Initial Development toward Non-Invasive Drug Monitoring via Untargeted Mass Spectrometric Analysis of Human Skin.
Drug monitoring is crucial for providing accurate and effective care; however, current methods (e.g., blood draws) are inconvenient and unpleasant. We aim to develop a non-invasive method for the detection and monitoring of drugs via human skin. The initial development toward this aim required information about which drugs, taken orally, can be detected via the skin. Untargeted liquid chromatography-mass spectrometry (LC-MS) was used as it was unclear if drugs, known drug metabolites, or other transformation products were detectable. In accomplishing our aim, we analyzed samples obtained by swabbing the skin of 15 kidney transplant recipients in five locations (forehead, nasolabial area, axillary, backhand, and palm), bilaterally, on two different clinical visits. Untargeted LC-MS data were processed using molecular networking via the Global Natural Products Social Molecular Networking platform. Herein, we report the qualitative detection and location of drugs and drug metabolites. For example, escitalopram/citalopram and diphenhydramine, taken orally, were detected in forehead, nasolabial, and hand samples, whereas N-acetyl-sulfamethoxazole, a drug metabolite, was detected in axillary samples. In addition, chemicals associated with environmental exposure were also detected from the skin, which provides insight into the multifaceted chemical influences on our health. The proof-of-concept results presented support the finding that the LC-MS and data analysis methodology is currently capable of the qualitative assessment of the presence of drugs directly via human skin
Recommended from our members
Digitizing mass spectrometry data to explore the chemical diversity and distribution of marine cyanobacteria and algae.
Natural product screening programs have uncovered molecules from diverse natural sources with various biological activities and unique structures. However, much is yet underexplored and additional information is hidden in these exceptional collections. We applied untargeted mass spectrometry approaches to capture the chemical space and dispersal patterns of metabolites from an in-house library of marine cyanobacterial and algal collections. Remarkably, 86% of the metabolomics signals detected were not found in other available datasets of similar nature, supporting the hypothesis that marine cyanobacteria and algae possess distinctive metabolomes. The data were plotted onto a world map representing eight major sampling sites, and revealed potential geographic locations with high chemical diversity. We demonstrate the use of these inventories as a tool to explore the diversity and distribution of natural products. Finally, we utilized this tool to guide the isolation of a new cyclic lipopeptide, yuvalamide A, from a marine cyanobacterium
Transcriptional and Functional Analysis of the Effects of Magnolol: Inhibition of Autolysis and Biofilms in Staphylococcus aureus
BACKGROUND: The targeting of Staphylococcus aureus biofilm structures are now gaining interest as an alternative strategy for developing new types of antimicrobial agents. Magnolol (MOL) shows inhibitory activity against S. aureus biofilms and Triton X-100-induced autolysis in vitro, although there are no data regarding the molecular mechanisms of MOL action in bacteria. METHODOLOGY/PRINCIPAL FINDINGS: The molecular basis of the markedly reduced autolytic phenotype and biofilm inhibition triggered by MOL were explored using transcriptomic analysis, and the transcription of important genes were verified by real-time RT-PCR. The inhibition of autolysis by MOL was evaluated using quantitative bacteriolytic assays and zymographic analysis, and antibiofilm activity assays and confocal laser scanning microscopy were used to elucidate the inhibition of biofilm formation caused by MOL in 20 clinical isolates or standard strains. The reduction in cidA, atl, sle1, and lytN transcript levels following MOL treatment was consistent with the induced expression of their autolytic repressors lrgA, lrgB, arlR, and sarA. MOL generally inhibited or reversed the expression of most of the genes involved in biofilm production. The growth of S. aureus strain ATCC 25923 in the presence of MOL dose-dependently led to decreases in Triton X-100-induced autolysis, extracellular murein hydrolase activity, and the amount of extracellular DNA (eDNA). MOL may impede biofilm formation by reducing the expression of cidA, a murein hydrolase regulator, to inhibit autolysis and eDNA release, or MOL may directly repress biofilm formation. CONCLUSIONS/SIGNIFICANCE: MOL shows in vitro antimicrobial activity against clinical and standard S. aureus strains grown in planktonic and biofilm cultures, suggesting that the structure of MOL may potentially be used as a basis for the development of drugs targeting biofilms
Fungal-bacterial interaction selects for quorum sensing mutants with increased production of natural antifungal compounds
Soil microorganisms coexist and interact showing antagonistic or mutualistic behaviors. Here we show that an environmental strain of Bacillus subtilis undergoes heritable phenotypic variation upon interaction with the soil fungal pathogen Setophoma terrestris (ST). Metabolomics analysis revealed differential profiles in B. subtilis before (pre-ST) and after (post-ST) interacting with the fungus, which paradoxically involved the absence of lipopeptides surfactin and plipastatin and yet acquisition of antifungal activity in post-ST variants. The profile of volatile compounds showed that 2-heptanone and 2-octanone were the most discriminating metabolites present at higher concentrations in post-ST during the interaction process. Both ketones showed strong antifungal activity, which was lost with the addition of exogenous surfactin. Whole-genome analyses indicate that mutations in ComQPXA quorum-sensing system, constituted the genetic bases of post-ST conversion, which rewired B. subtilis metabolism towards the depletion of surfactins and the production of antifungal compounds during its antagonistic interaction with S. terrestris.Fil: AlbarracĂn Orio, Andrea Georgina. Universidad CatĂłlica de CĂłrdoba. Instituto de Investigaciones en Recursos Naturales y Sustentabilidad JosĂ© Sanchez Labrador S. J. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Centro CientĂfico TecnolĂłgico Conicet - CĂłrdoba. Instituto de Investigaciones en Recursos Naturales y Sustentabilidad JosĂ© Sanchez Labrador S. J.; Argentina. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Centro CientĂfico TecnolĂłgico Conicet - CĂłrdoba. Centro de Investigaciones en QuĂmica BiolĂłgica de CĂłrdoba. Universidad Nacional de CĂłrdoba. Facultad de Ciencias QuĂmicas. Centro de Investigaciones en QuĂmica BiolĂłgica de CĂłrdoba; Argentina. Universidad Nacional de CĂłrdoba. Facultad de Ciencias QuĂmicas. Departamento de QuĂmica BiolĂłgica; ArgentinaFil: Petras, Daniel. University of California at San Diego. Skaggs School of Pharmacy & Pharmaceutical Sciences. Collaborative Mass Spectrometry Innovation Center; Estados Unidos. University of California at San Diego. Scripps Institution of Oceanography; Estados UnidosFil: Tobares, Romina AlĂn. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Centro CientĂfico TecnolĂłgico Conicet - CĂłrdoba. Centro de Investigaciones en QuĂmica BiolĂłgica de CĂłrdoba. Universidad Nacional de CĂłrdoba. Facultad de Ciencias QuĂmicas. Centro de Investigaciones en QuĂmica BiolĂłgica de CĂłrdoba; Argentina. Universidad Nacional de CĂłrdoba. Facultad de Ciencias QuĂmicas. Departamento de QuĂmica BiolĂłgica; ArgentinaFil: Aksenov, Alexander. University of California at San Diego. Skaggs School of Pharmacy & Pharmaceutical Sciences. Collaborative Mass Spectrometry Innovation Center; Estados Unidos. University of California at San Diego. Scripps Institution of Oceanography; Estados UnidosFil: Wang, Mingxun. University of California at San Diego. Skaggs School of Pharmacy & Pharmaceutical Sciences. Collaborative Mass Spectrometry Innovation Center; Estados UnidosFil: Juncosa, Florencia. Universidad CatĂłlica de CĂłrdoba. Instituto de Investigaciones en Recursos Naturales y Sustentabilidad JosĂ© Sanchez Labrador S. J. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Centro CientĂfico TecnolĂłgico Conicet - CĂłrdoba. Instituto de Investigaciones en Recursos Naturales y Sustentabilidad JosĂ© Sanchez Labrador S. J.; ArgentinaFil: Sayago, Pamela MarĂa del Luján. Universidad CatĂłlica de CĂłrdoba. Instituto de Investigaciones en Recursos Naturales y Sustentabilidad JosĂ© Sanchez Labrador S. J. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Centro CientĂfico TecnolĂłgico Conicet - CĂłrdoba. Instituto de Investigaciones en Recursos Naturales y Sustentabilidad JosĂ© Sanchez Labrador S. J.; ArgentinaFil: Moyano, Alejandro Jose. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Centro CientĂfico TecnolĂłgico Conicet - CĂłrdoba. Centro de Investigaciones en QuĂmica BiolĂłgica de CĂłrdoba. Universidad Nacional de CĂłrdoba. Facultad de Ciencias QuĂmicas. Centro de Investigaciones en QuĂmica BiolĂłgica de CĂłrdoba; Argentina. Universidad Nacional de CĂłrdoba. Facultad de Ciencias QuĂmicas. Departamento de QuĂmica BiolĂłgica; ArgentinaFil: Dorrestein, Pieter. University of California at San Diego. Skaggs School of Pharmacy & Pharmaceutical Sciences. Collaborative Mass Spectrometry Innovation Center; Estados UnidosFil: Smania, Andrea. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Centro CientĂfico TecnolĂłgico Conicet - CĂłrdoba. Centro de Investigaciones en QuĂmica BiolĂłgica de CĂłrdoba. Universidad Nacional de CĂłrdoba. Facultad de Ciencias QuĂmicas. Centro de Investigaciones en QuĂmica BiolĂłgica de CĂłrdoba; Argentina. Universidad Nacional de CĂłrdoba. Facultad de Ciencias QuĂmicas. Departamento de QuĂmica BiolĂłgica; Argentin
Recommended from our members
Molecular and Microbial Microenvironments in Chronically Diseased Lungs Associated with Cystic Fibrosis.
To visualize the personalized distributions of pathogens and chemical environments, including microbial metabolites, pharmaceuticals, and their metabolic products, within and between human lungs afflicted with cystic fibrosis (CF), we generated three-dimensional (3D) microbiome and metabolome maps of six explanted lungs from three cystic fibrosis patients. These 3D spatial maps revealed that the chemical environments differ between patients and within the lungs of each patient. Although the microbial ecosystems of the patients were defined by the dominant pathogen, their chemical diversity was not. Additionally, the chemical diversity between locales in the lungs of the same individual sometimes exceeded interindividual variation. Thus, the chemistry and microbiome of the explanted lungs appear to be not only personalized but also regiospecific. Previously undescribed analogs of microbial quinolones and antibiotic metabolites were also detected. Furthermore, mapping the chemical and microbial distributions allowed visualization of microbial community interactions, such as increased production of quorum sensing quinolones in locations where Pseudomonas was in contact with Staphylococcus and Granulicatella, consistent with in vitro observations of bacteria isolated from these patients. Visualization of microbe-metabolite associations within a host organ in early-stage CF disease in animal models will help elucidate the complex interplay between the presence of a given microbial structure, antibiotics, metabolism of antibiotics, microbial virulence factors, and host responses.IMPORTANCE Microbial infections are now recognized to be polymicrobial and personalized in nature. Comprehensive analysis and understanding of the factors underlying the polymicrobial and personalized nature of infections remain limited, especially in the context of the host. By visualizing microbiomes and metabolomes of diseased human lungs, we reveal how different the chemical environments are between hosts that are dominated by the same pathogen and how community interactions shape the chemical environment or vice versa. We highlight that three-dimensional organ mapping methods represent hypothesis-building tools that allow us to design mechanistic studies aimed at addressing microbial responses to other microbes, the host, and pharmaceutical drugs
Discovering and linking public omics data sets using the Omics Discovery Index.
Biomedical data are being produced at an unprecedented rate owing to the falling cost of experiments and wider access to genomics, transcriptomics, proteomics and metabolomics platforms1, 2. As a result, public deposition of omics data is on the increase. This presents new challenges, including finding ways to store, organize and access different types of biomedical data stored on different platforms. Here, we present the Omics Discovery Index (OmicsDI; http://www.omicsdi.org), an open-source platform that enables access, discovery and dissemination of omics data sets
A proteomics sample metadata representation for multiomics integration and big data analysis
The amount of public proteomics data is rapidly increasing but there is no standardized format to describe the sample metadata and their relationship with the dataset files in a way that fully supports their understanding or reanalysis. Here we propose to develop the transcriptomics data format MAGE-TAB into a standard representation for proteomics sample metadata. We implement MAGE-TAB-Proteomics in a crowdsourcing project to manually curate over 200 public datasets. We also describe tools and libraries to validate and submit sample metadata-related information to the PRIDE repository. We expect that these developments will improve the reproducibility and facilitate the reanalysis and integration of public proteomics datasets.publishedVersio
- …